Vericel Reports Three-Year Follow-Up Results From Phase 3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study of MACI(TM) Implant

CAMBRIDGE, Mass., March 25, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq: VCEL ), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported that positive results from the three-year extension of the Phase 3 SUMMIT study with MACI™ (matrix-applied characterized autologous cultured chondrocytes) were presented at the annual meeting of the American Association of Orthopedic Surgeons in Las Vegas. In a poster presentation (number P169) entitled "SUMMIT Trial: Matrix-induced Autologous Chondrocyte Implant versus Microfracture at 3 Years," Professor Mats Brittberg, Cartilage Research Unit, University of Gothenburg, Sweden, and colleagues reported that patients followed for three years following treatment with MACI had consistent results as those reported previously in the two-year SUMMIT trial.

In the open-label, multi-center Phase 3 SUMMIT study, 144 patients with symptomatic articular cartilage defects in the knee were randomized to receive treatment with MACI implant or microfracture bone marrow stimulation (MFX) and followed for two years. The study found that treatment with MACI was clinically and statistically significantly better than MFX, with similar structural repair tissue and safety. The SUMMIT study concluded that "MACI offers a more efficacious alternative than MFX with a similar safety profile for the treatment of symptomatic articular cartilage defects of the knee." 1

In the SUMMIT Extension trial, 128 patients (men and women aged 18 to 55) from the original SUMMIT study continue to be followed. The co-primary endpoints of the extension study are change in knee injury and osteoarthritis outcome (KOOS) pain and function scores at year 3, the same primary endpoint from the two-year SUMMIT trial. Patients treated with MACI versus MFX continue to show a statistically significant improvement from baseline in the co-primary endpoint of KOOS pain and function at year 3 (p = 0.046) with higher responder rates in the MACI group (81.5%) than in the MFX group (66.7%). Patients treated with MACI versus MFX also showed significant improvement in knee-related quality of life and other measures. The authors concluded that "the co-primary endpoints of pain and function showed significant improvement with MACI, which was statistically significantly better than with MFX." The incidences of treatment emergent adverse events and serious adverse events were similar between treatment groups at year 3 and no unexpected safety findings were reported.

David Recker, M.D., Vericel's chief medical officer, stated: "These findings appear to support the positive risk-benefit profile of MACI implantation in patients who require knee cartilage repair surgery that was first demonstrated in the pivotal Phase 3 SUMMIT study. We are extremely encouraged by the favorable clinical and efficacy of MACI compared to MFX after 3 years of follow-up."

1 D. Saris et al., "Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture; Two-Year Follow-up of a Prospective Randomized Trial," The American Journal of Sports Medicine, Vol. 42, No. 6, April 2014

About MACI

MACI is a third-generation autologous chondrocyte implantation (ACI) product for the treatment of focal chondral cartilage defects in the knee. MACI has been approved but is not currently marketed in Europe and is a Phase 3 product candidate in the United States. The pivotal clinical trial supporting MACI registration in Europe (Superiority of MACI Implant to Microfracture Treatment, or SUMMIT) demonstrated a statistically significant and clinically meaningful improvement in the co-primary endpoint of pain and function for those patients treated with a MACI implant compared to microfracture, the previous standard of care.  MACI has the potential advantages of a shorter, less-invasive surgical procedure and faster recovery period than current biological treatments for knee cartilage repair. Vericel plans to meet with the FDA this year to discuss the requirements for registration of MACI in the United States.

About Vericel Corporation

Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.  The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com .

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products and growth in revenues, intended product development, clinical activity timing, integration of the acquired business, and objectives and expectations regarding our company described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, integration of the acquired business, clinical trial and product development activities, regulatory approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law. 

Chad Rubin The Trout Group (646) 378-2947 Lee Stern The Trout Group (646) 378-2922

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading